BLRX - BioLineRx Ltd.

2.65
-0.060   -2.264%

Share volume: 9,538
Last Updated: 03-06-2026
Pharmaceutical Products/Pharmaceutical Preparations: 3.14%

PREVIOUS CLOSE
CHG
CHG%
$2.71
-0.06
-0.02%
5D - 1M - 3M - 1Y - 3Y - 5Y - 10Y - 15Y
Overview Charts Fundamental analysis Historical prices Events Documents Notes Dividends
Fundamental analysis
5%
Profitability 0%
Dept financing 7%
Liquidity 38%
Performance 0%
Company vs Stock growth
vs
+ Add row to compare
Performance
5 Days
-5.69%
1 Month
-12.25%
3 Months
-20.18%
6 Months
-27.20%
1 Year
-15.87%
2 Year
124.58%
Key data
Stock price
$2.65
P/E Ratio 
0.00
DAY RANGE
$2.56 - $2.73
EPS 
-$3.18
52 WEEK RANGE
$2.30 - $7.77
52 WEEK CHANGE
-$15.87
MARKET CAP 
96.603 M
YIELD 
N/A
SHARES OUTSTANDING 
79.939 M
DIVIDEND
$0.00
EX-DIVIDEND DATE
01-30-2025
NEXT EARNINGS DATE
N/A
BETA 
1.11
PUBLIC FLOAT 
$0
AVERAGE 10 VOLUME 
$9,281
AVERAGE 30 VOLUME 
$10,934
Company detail
CEO: Philip A. Serlin
Region: US
Website: biolinerx.com
Employees: 40
IPO year: 2011
Issue type: American Depository Receipt (ADR’s)
Market: XNAS
Industry: Pharmaceutical Products/Pharmaceutical Preparations
Sector: Manufacturing

Motixafortide, a peptide, has completed Phase 3 clinical trials for the treatment of autologous stem cell mobilization. It is also developing AGI-134, an immuno-oncology agent, and BL-5010, a customized, proprietary, pen-like applicator for the non-surgical removal of skin lesions.

Recent news